Inari Agriculture
UK-founded seed design company using CRISPR gene editing to improve crop traits.
On the record
Checkpoint: Corteva Agriscience v. Inari patent and trade-secret trial verdict (D. Del., Case No. 1:23-cv-01059)
The call
Inari has real gene-editing technology and industry partnerships but no verified commercial revenue yet, with a Corteva patent trial in September 2026 that could reshape its path either way.
Inari Agriculture uses advanced gene-editing technology to create better seeds and crops. The company has built genuine technical advantages, including proprietary genomic data and a track record with regulators, but has not yet sold products at commercial scale. However, this space is not blocked off: Corteva Agriscience, Bayer, and Syngenta all have the money, distribution networks, and existing seed libraries to build similar gene-edited crops themselves, and Corteva is currently suing Inari while also funding a different gene-editing competitor called Pairwise. The single thing that could reshape the picture is the patent and trade-secrets trial against Corteva scheduled for September 2026; a win could validate Inari's intellectual property and clear a path forward, while a loss could devastate the company's legal standing and valuation.
Why
01
AI pressure: None apparent. Inari uses computational and AI-assisted genome design internally; no AI product is displacing its seed trait business today. Could AI do the core job? Only partly.
02
Bigger players: Corteva Agriscience. Corteva is suing Inari over patents and trade secrets while funding rival gene-editing startup Pairwise, and Bayer and Syngenta hold the distribution Inari needs. Could a giant copy it? Yes, easily.
03
What protects it. Proprietary multiplex CRISPR platform and genomic data, plus seed-industry partnerships like Mertec and MS Technologies for distribution access.
What would change this call
Verdict in Corteva v. Inari trial (D. Del., Case No. 1:23-cv-01059) around Sept 23, 2026. An adverse ruling would restrict Inari's commercialization and validate Corteva's IP pressure.
USDA APHIS decision on Inari's gene-edited soybean lines. Approval or delay shows whether regulatory moat is converting into market access.
Announcement of a second layoff round or further West Lafayette cost-cutting. Would indicate cash strain and weakening ability to compete for seed-company deals.
USDA APHIS decision on Inari's gene-edited soybean lines. Approval or delay shows whether regulatory moat is converting into market access.
Announcement of a second layoff round or further West Lafayette cost-cutting. Would indicate cash strain and weakening ability to compete for seed-company deals.
Key numbers
- Raised $144M at $2.17B post-money valuation
- Total equity raised exceeds $720M
- Laid off 64 employees, ~33% of Indiana facility
Named risks
- Adverse verdict in Corteva v. Inari trial (Sept 23, 2026) could impose damages or block commercialization.
- Company remains pre-commercial at scale despite raising over $720M as of January 2025.
- First known layoffs (64 employees, Jan 2026) may signal cash burn or strategic contraction.
- CEO transitions in 2025 (health-related departure, interim CEO, new permanent CEO) created leadership instability.
- Local government scrutiny over unmet investment commitments in West Lafayette, Indiana (July 2026).
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Corteva Agriscience | contesting | Suing Inari on patents/trade secrets with trial set September 23, 2026, while funding rival Pairwise |
| Pairwise Plants | gaining on | Raised $40M Series C on April 14, 2026 backed by Corteva Catalyst and Leaps by Bayer |
| Bayer Crop Science | contesting | Dominant germplasm and distribution; DOJ secured commitments from Bayer on seed-market competition, May 2026 |
| Syngenta | contesting | Incumbent controlling dominant germplasm and distribution in corn/soy/wheat as of 2025-2026 |
Questions people ask
- Is Inari Agriculture profitable in 2026?
- No. Inari describes itself as only 'entering commercialization' as of January 7, 2025, working with seed-company customers in demonstration plots rather than end-farmers. No verified revenue at scale has been reported, and the company filed its first known layoffs in January 2026.
- Could AI replace what Inari Agriculture does?
- Partially. Inari already uses AI to identify gene-edit candidates, jumping from about 50 candidate soybean genes in 2022 to roughly 1,200 by 2024 (company-reported to USDA). But its wet-lab CRISPR execution, proprietary trait datasets, and USDA regulatory track record are not directly replaceable by AI alone.
- Who is Inari Agriculture's biggest competitor threat?
- Corteva Agriscience is both suing Inari over patents and trade secrets (trial set for September 23, 2026, D. Del. Case No. 1:23-cv-01059) and, via Corteva Catalyst, funded a $40 million Series C for rival Pairwise Plants on April 14, 2026.
- Who owns Inari Agriculture?
- Inari is privately held and venture-backed, incubated inside Flagship Pioneering starting in 2016. Its January 2025 Series G ($144 million at a $2.17 billion post-money valuation) included new investor Abu Dhabi Investment Authority alongside Hanwha Impact and Flagship Pioneering.
- How much money has Inari Agriculture raised, and what is it worth?
- Inari has raised over $720 million in total equity as of January 7, 2025. Its most recent priced round was a $144 million Series G on January 7, 2025 at a $2.17 billion post-money valuation, up about 32% from $1.65 billion in January 2024.
- Has Inari Agriculture had layoffs?
- Yes. Inari filed a WARN notice on January 20, 2026 for a mass layoff of 64 employees at its West Lafayette, Indiana facility, reported to be roughly 33% of that site's workforce, described by the company as due to changing business needs.
Timeline
- 2026-07-07West Lafayette council found Inari lacking on tax abatement deal commitments
- 2026-05-11DOJ filed Statement of Interest in Corteva v. Inari case citing anti-competition executive order
- 2026-04-14Pairwise Plants raised $40M Series C backed by Corteva Catalyst
- 2026-03-02Federal court issued memorandum opinion in Corteva v. Inari litigation
- 2026-01-20Inari filed WARN notice for 64 layoffs at West Lafayette, Indiana facility
- 2025-12-08Federal Circuit denied Inari's mandamus petition over Pioneer Hi-Bred patent
- 2025-10-29Lisa Nunez Safarian appointed permanent CEO, effective November 4, 2025
- 2025-06-02Co-founder Ignacio Martinez named interim CEO
- 2025-04CEO Ponsi Trivisvavet stepped down for health reasons
- 2025-01-07Closed $144M Series G at $2.17B post-money valuation
Revision history
25 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Inari Raises $144 Million, Paving Path to Long-Term Growth (2025-01-07)
- AgTech Startup Inari Gets $2.17 Billion Valuation in Latest Funding Round (2025-01-07)
- Company Profile (2026-06-30)
- Seed gene-editing startup Inari eyes commercialization with $144m round (2025-01-07)
- Inari - Overview, News & Similar companies
- Inari Announces Co-Founder Ignacio Martinez as Interim CEO (2025-06-02)
- Inari Appoints Lisa Nunez Safarian Chief Executive Officer (2025-10-29)
- WARN Notification (2026-01-20)
- Iowa Soybean Research Center Welcomes Inari as Industry Partner (2025-10-07)
- Inari Broadens Access to Soybean Genetics (2026)
- 23-132-01cbidel1_a2.pdf
- Inari Agriculture Raises $144M in Funding (2025-01-07)